1426073-33-7

Basic information

• Product Name: 4-Bromo-2-fluoro-3-methoxybenzonitrile
• Synonyms: 4-Bromo-2-fluoro-3-methoxybenzonitrile;6-Bromo-3-cyano-2-fluoroanisole
• CAS NO: 1426073-33-7
• Molecular Formula: C8H5BrFNO
• Molecular Weight: 230.0338032
• Mol File: 1426073-33-7.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-Bromo-2-fluoro-3-methoxybenzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Bromo-2-fluoro-3-methoxybenzonitrile(1426073-33-7)
• EPA Substance Registry System: 4-Bromo-2-fluoro-3-methoxybenzonitrile(1426073-33-7)

Safety Data

• Hazardous Substances Data: 1426073-33-7(Hazardous Substances Data)

Usage

Uses

4-Bromo-2-fluoro-3-methoxybenzonitrile is used as a reagent in the synthesis of piperazinopiperazines and related compounds as renal outer medullary potassium (ROMK) channel inhibitors.

Upstream product

• 367-12-4 2-fluorophenol 
• 194804-92-7 4-bromo-2-fluoro-3-methoxybenzoic acid 
• 845829-94-9 1-bromo-3-fluoro-2-methoxybenzene 
• 437-83-2 3-fluoro-2-methoxyaniline 
• 1526-17-6 2-fluoro-6-nitrophenol 
• 484-94-6 1-fluoro-2-methoxy-3-nitrobenzene 

Relevant articles and documents

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

INHIBITORS OF THE RENAL OUTER MEDULLARY POTASSIUM CHANNEL

The present invention provides compounds of Formula Ia and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.